Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) today and set a price target of $25.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sumant Kulkarni has given his Buy rating due to a combination of factors that highlight the potential of Zevra Therapeutics. The company reported impressive sales figures for Miplyffa, their treatment for Niemann-Pick Type C, which significantly exceeded expectations. This strong performance, combined with the positive trajectory of the product’s launch, suggests that the market may be undervaluing the company’s rare disease strategy.
Additionally, Zevra is making progress with Olpruva for urea cycle disorders and has recently completed a significant sale of a pediatric priority review voucher, which strengthens their financial position. The company’s strategic initiatives and financial flexibility, along with the promising outlook for Miplyffa in both the US and potential European markets, contribute to the Buy rating. Despite some model adjustments, the price target remains steady, reflecting confidence in the company’s future prospects.
Kulkarni covers the Healthcare sector, focusing on stocks such as CervoMed, ACADIA Pharmaceuticals, and Neurocrine. According to TipRanks, Kulkarni has an average return of -0.1% and a 37.94% success rate on recommended stocks.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $19.00 price target.